GSDME and triple-negative breast carcinoma: For instance, decitabine has been shown to upregulate GSDME expression, shifting apoptosis to pyroptosis in tumor cells [67], and pretreatment with decitabine has augmented the effectiveness of nanodrug-delivered cisplatin in triple-negative breast cancer [183].